According to new research published in the American Heart Association journal Circulation, aspirin may be a possible alternative for patients who can’t take long-term anticoagulant drugs to prevent blood clots.
The International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism (INSPIRE) analysis looked at two similar independent studies in which a total of 1,224 patients who were taking aspirin 100mg daily to treat blood clots were monitored for 2 years. Results of the analysis showed that aspirin reduced the risk of recurring venous thromboembolism by up to 42% (hazard ratio [HR] 0.58, 95% CI: 0.40–0.85, P=0.005).
Compared to an anticoagulant like warfarin, aspirin does not require laboratory monitoring, and is associated with approximately a 10-fold lower incidence of bleeding compared to oral anticoagulants.
The researchers still recommend patients talk to their doctor about taking aspirin after discontinuing treatment with anticoagulants.
For more information visit AHAJournals.org.